Welcome!

News Feed Item

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012

Late-Stage ARIKACE® Clinical Trials in Two Initial Indications on Schedule to Report Results in 2013

MONMOUTH JUNCTION, N.J., Nov. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported results for the third quarter and nine-months ended September 30, 2012.

Key Recent Highlights

  • Appointed Will Lewis, Co-Founder and former President and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), to the position of President and Chief Executive Officer, and Andrew Drechsler, former Chief Financial Officer of VaxInnate Corporation, to the position of Chief Financial Officer
  • Significantly enhanced financial position through $25.7 million registered direct offering of common stock and $20 million loan agreement with Hercules Technology Growth Capital
  • Granted second composition of matter patent for ARIKACE® by U.S. Patent and Trademark Office, providing exclusivity for ARIKACE through mid-August 2028
  • Phase 3 study (CLEAR-108) of ARIKACE in patients with cystic fibrosis who have Pseudomonas aeruginosa lung infections continues to enroll and remains on schedule for top-line results in mid-2013
  • Phase 2 trial (TARGET-NTM) of ARIKACE in patients with non-tuberculous mycobacteria lung infections continues to enroll and remains on schedule for top-line results by end of 2013

"The significant progress and strategic changes made by Insmed in the third quarter have positioned us at the threshold of several significant potential value-creating milestones," said Will Lewis, President and CEO of Insmed. "With another $25.7 million in capital added and the expected reporting of late-stage clinical data next year, we have quickly aligned the Company for the successful commercial launch of ARIKACE in the U.S. and Europe, following receipt of the required regulatory approvals."

Financial Results

Quarter Ended September 30, 2012

For the third quarter of 2012, Insmed posted a net loss attributable to common stockholders of $9.4 million, or $0.38 per common share – basic and diluted, as compared to a net loss of $34.6 million, or $1.39 per common share – basic and diluted, for the three months ended September 30, 2011.  The $25.2 million improvement in net loss was primarily due to a non-cash impairment charge of $26.0 million in the third quarter of 2011 relating to a write-down of in-process research and development and goodwill.  This reduction in expenses in the third quarter of 2012 was offset by a $0.4 million decline in IPLEX® discontinued product revenue, a $0.2 million reduction in investment income and a $0.2 million increase in interest expense.

Insmed did not record any revenues for the three months ended September 30, 2012, as compared to $0.4 million in revenues reported for the three months ended September 30, 2011.  The $0.4 million decrease was due to the elimination of discontinued product revenue.

Research and development (R&D) expenses decreased to $5.5 million in the three months ended September 30, 2012, from $6.9 million for the three months ended September 30, 2011.  The decrease of $1.4 million in 2012 is primarily attributable to a reduction of $2.3 million in development costs associated with initiating two ARIKACE-related clinical trials, as compared to the same period in 2011, when the clinical program was initially being planned.  This reduction was partially offset by an increase of $0.4 million in manufacturing costs associated primarily with initiating a non-clinical study and the build-up of clinical trial drug supply for the ongoing Phase 3 (CLEAR-108) and Phase 2 (TARGET-NTM) clinical studies, a $0.4 million increase in regulatory and quality assurance costs driven by the purchase of comparator drugs used in Insmed's clinical study and a $0.1 million increase in compensation-related expenses, as headcount increased to support the ongoing trials.

General and administrative expenses increased $1.3 million to $3.8 million in the three months ended September 30, 2012 from $2.5 million for the three months ended September 30, 2011 due primarily to employee separation costs recorded in the third quarter of 2012.

Investment income for the third quarter of 2012 of $0.2 million was $0.2 million lower than the corresponding period in 2011 due to the lower cash balance available for investment. Interest expense was $0.2 million higher than the third quarter of 2011 due to payments associated with the recent debt financing.

Nine Months Ended September 30, 2012

Net loss attributable to common stockholders for the nine months ended September 30, 2012 was $25.9 million, or $1.04 per common share – basic and diluted, compared to a net loss of $60.7 million, or $2.66 per common share – basic and diluted, for the nine months ended September 30, 2011.  The $34.8 million reduction in the net loss period on period was primarily due to the combination of the previously mentioned $26.0 million non-cash impairment charge incurred in the third quarter of 2011 and the $9.2 million non-cash charge for the beneficial conversion feature of the Series B Conditional Convertible Preferred Stock incurred in the first quarter of 2011, which increased the net loss attributable to holders of our common shares in the 2011 period and, in turn, increased our loss per common share on a basic and diluted basis in the 2011 period by $0.40.  The beneficial conversion charge represents the $1.00 difference between the conversion price of the Series B Conditional Convertible Preferred Stock of $7.10 per share and its carrying value of $6.10 per share.  The carrying value of the Series B Preferred Stock was based on its fair value at issuance, which was estimated using the common stock price reduced for a lack of marketability between the issuance date and the anticipated date of conversion.  Additionally, a reduction in other operating expenses of $3.3 million in the nine months ended September 30, 2012 was fully offset by a revenue reduction of $3.0 million, a decline in investment income of $0.5 million and an increase in interest expense of $0.2 million.

Insmed did not record any revenues for the nine months ended September 30, 2012.  Insmed reported $3.0 million in revenues for the nine months ended September 30, 2011. The $3.0 million decrease was due to the inclusion of $2.7 million of product revenue and the receipt of $0.3 million in license fees for our discontinued CISPLATIN lipid complex program in the nine months ended September 30, 2011, as compared to no revenues or license fees from this program in the current year.

R&D expenses decreased to $17.6 million in the nine months ended September 30, 2012 from $21.4 million for the nine months ended September 30, 2011.  The decrease of $3.8 million is again primarily attributable to a reduction of $4.5 million in development costs and $0.9 million for regulatory and quality assurance costs associated with initiating two ARIKACE related clinical trials, as compared to when the clinical program was initially being planned in the same period in 2011.  These reductions were partially offset by an increase of $1.5 million in manufacturing costs in the nine months ended September 30, 2012 associated with initiating a non-clinical study and building drug supply for the ongoing CLEAR-108 and TARGET-NTM clinical trials.

General and administrative expenses increased by $0.6 million to $9.0 million in the nine months ended September 30, 2012.  The increase was due largely to the $1.2 million employee separation costs incurred in the third quarter of 2012, offset in part by the absence of finance, legal and consulting fees which were incurred in the nine months ended September 30, 2011 in relation to post Transave merger matters and the March 2011 reverse stock split transaction.

Investment income decreased to $0.9 million in the nine months ended September 30, 2012, from $1.4 million in the nine months ended September 30, 2011.  The decrease is a result of the lower overall average cash and short-term investments balance for the current year to date period, as compared to the year to date period ended September 30, 2011.

Liquidity Position

As of September 30, 2012, Insmed had total cash, cash equivalents, short-term investments, and certificate of deposits on hand totalling $91.9 million, consisting of $89.7 million in cash and short-term investments and $2.1 million in a certificate of deposit, as compared to $78.4 million of cash on hand as of December 31, 2011.  The $13.5 million increase in total cash was due primarily to the $35.4 million of net proceeds received in relation to the third quarter financing activities.  These financing activities consisted of $9.7 from debt and $25.7 million from the sale of common stock, which was partially offset by $22.1 million used in operating activities.  

Conference Call

To participate in today's live conference call, please dial 800-573-4754 (U.S. callers) or 617-224-4325 (international), and provide passcode 53958411.  A live webcast of the call will also be available at http://www.media-server.com/m/p/86at7fkj.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.  The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning today at 10:30 AM ET, at 1-888-286-8010 (U.S. callers) or +1-617-801-6888 (international), using passcode 37999986.

About Insmed

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious orphan lung diseases through the development and commercialization of novel, targeted inhalation therapies in orphan patient populations with critical unmet needs.  Insmed's lead candidate, ARIKACE®, is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for at least two identified patient populations: cystic fibrosis (CF) patients with Pseudomonas lung infections and patients with nontuberculous mycobacteria lung infections (NTM). Following positive phase 2 results in CF patients, Insmed's phase 3 registrational study of ARIKACE (CLEAR-108) in Europe and Canada is well underway, as is the U.S. Phase 2 trial in NTM (TARGET-NTM). The Company expects to report clinical results from both the CF Phase 3 and NTM Phase 2 studies in 2013 and currently is preparing for regulatory filings and for commercialization, if and when regulatory approvals are obtained.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934.  Words, and variations of words, such as "intend", "expect", "will", "anticipate", "believe", "continue", "propose" and similar expressions are intended to identify forward-looking statements.  Investors are cautioned that such statements in this release, including statements relating to our financial position, our estimates regarding our capital requirements, our expected cash position and our needs for additional financing, our ability to access additional funds under the Hercules loan agreement, results of operations, the status, results and timing of results of pre-clinical studies and clinical trials and pre-clinical and clinical data described herein, the timing of and costs associated with pre-clinical studies and clinical trials, the development of our products, our estimates of the size of the potential markets for our product candidates, and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Such risks and uncertainties include, without limitation, failure or delay of U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting our product development, delays in product development or clinical trials, patent disputes involving currently developing products, unexpected regulatory actions, delays or requests, the failure of future clinical trials, inability to successfully develop our product candidates or receive necessary regulatory approvals, inability to make  product candidates commercially successful, changed in anticipated expenses, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2011 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to update these forward-looking statements to reflect events or circumstances or changes in expectations.

Investor Relations Contact:
Brian Ritchie – FTI Consulting
212-850-5683
[email protected]

Media Contact:
Irma Gomez-Dib – FTI Consulting
212-850-5761
[email protected] 

 

INSMED INCORPORATED

Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share data)








September 30,


December 31,



2012


2011

Assets





Current assets:





  Cash and cash equivalents


$                    44,989


$                    14,848

  Short-term investments


44,759


61,424

  Accounts receivable


-


757

  Prepaid expenses and other current assets


605


370

Total current assets


90,353


77,399






Certificate of deposit


2,132


2,085

In-process research and development


58,200


58,200

Other


125


212

Fixed assets, net


1,647


1,937

Total assets


$                  152,457


$                  139,833






Liabilities and stockholders' equity





Current liabilities:





  Accounts payable


$                      2,985


$                      2,334

  Accrued expenses


836


800

  Accrued compensation


1,581


795

  Accrued lease expense, current


291


278

  Deferred rent


151


156

  Capital lease obligations, current


109


114

  Debt, current


592


-

Total current liabilities


6,545


4,477






Accrued lease expense, long-term


717


923

Capital lease obligations, long-term


80


166

Debt, long-term


8,503


-

Total liabilities


15,845


5,566






Stockholders' equity:





Common stock; $.01 par value; authorized shares





500,000,000; issued and outstanding shares, 31,178,954 

in 2012 and 24,833,301 in 2011


312


248

  Additional paid-in capital


455,560


427,743

  Accumulated deficit


(320,095)


(294,174)

  Accumulated other comprehensive income:





     Unrealized gain on investments


835


450

Total stockholders' equity


136,612


134,267

Total liabilities and stockholders' equity


$                      152,457


$                      139,833

 

 

 

INSMED INCORPORATED

Consolidated Statements of Comprehensive Operations (Unaudited)

(in thousands, except per share data)










 Three Months Ended


 Nine Months Ended


September 30,


September 30,


2012


2011


2012


2011









License fees

$           -


$            1


$           -


$        252

Other expanded access program income, net

-


434


-


2,762

Total revenues

-


435


-


3,014









Operating expenses:








Research and development

5,539


6,933


17,553


21,399

General and administrative

3,814


2,472


9,047


8,474

Impairment loss

-


25,990


-


25,990

Total operating expenses

9,353


35,395


26,600


55,863









Operating loss

(9,353)


(34,960)


(26,600)


(52,849)









Investment income

193


371


901


1,358

Interest expense

(222)


(2)


(225)


(9)

Gain on sale of asset, net

-


-


5


-

Loss before income taxes

(9,382)


(34,591)


(25,919)


(51,500)









Income tax expense

-


-


4


2









Net loss

(9,382)


(34,591)


(25,923)


(51,502)









Accretion of beneficial conversion charge

-


-


-


(9,175)









Net loss  attributable to common stockholders

$    (9,382)


$  (34,591)


$  (25,923)


$  (60,677)









Basic and diluted net loss attributable to common stockholders per common share

$      (0.38)


$      (1.39)


$      (1.04)


$      (2.66)









Weighted average basic and diluted common shares outstanding

25,013


24,833


24,916


22,848









Comprehensive loss

$    (9,183)


$  (34,837)


$  (25,538)


$  (51,624)

 

 

 

INSMED INCORPORATED

Consolidated Statements of Cash Flows (Unaudited)

(in thousands)










 Nine Months Ended




September 30,




2012


2011

Operating activities





Net loss


$       (25,923)


$     (51,502)

Adjustments to reconcile net loss to net cash (used in)





provided by operating activities:






Depreciation and amortization


412


233


Stock based compensation expense


1,518


1,091


Gain on sale of asset, net


(5)


-


Impairment loss


-


25,990


Amortization of financing costs


55


-


Changes in operating assets and liabilities:






  Accounts receivable


757


31


  Prepaid expenses and other assets


(175)


(352)


  Accounts payable


651


54


  Accrued expenses and deferred rent


31


296


  Accrued lease expenses


(193)


-


  Accrued compensation


786


-


  Deferred revenue


-


19


Net cash used in operating activities


(22,086)


(24,140)







Investing activities






  Purchase of fixed assets


(122)


(555)


  Proceeds from sale of asset


5


-


  Sales of short-term investments


17,050


26,018


  Purchases of short-term investments


-


(1,585)


Net cash provided by investing activities


16,933


23,878







Financing activities






Payments on capital lease obligations


(91)


(64)


Proceeds from issuance of debt, net of issuance and financing costs


9,726


-


Proceeds from issuance of common stock


25,659


32


Net cash provided by (used in) financing activities


35,294


(32)







Increase in cash and cash equivalents


30,141


(294)

Cash and cash equivalents at beginning of period


14,848


10,743







Cash and cash equivalents at end of period


$         44,989


$       10,449







Supplemental disclosures of cash flow information






Cash paid for interest


$              164


$                9


Cash paid for taxes, net


$                  4


$                2







Supplemental disclosures of non-cash investing and financing activities






Unrealized  gain on investments


$              385


$          (122)


Accretion of beneficial conversion charge


$                  -


$       (9,175)


Fair value of warrants in connection with debt


$              790


$                 -

 

 

 

SOURCE Insmed Incorporated

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As hybrid cloud becomes the de-facto standard mode of operation for most enterprises, new challenges arise on how to efficiently and economically share data across environments. In his session at 21st Cloud Expo, Dr. Allon Cohen, VP of Product at Elastifile, will explore new techniques and best practices that help enterprise IT benefit from the advantages of hybrid cloud environments by enabling data availability for both legacy enterprise and cloud-native mission critical applications. By rev...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous a...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, will provide a fun and simple way to introduce Machine Leaning to anyone and everyone. Together we will solve a machine learning problem and find an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intellige...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
Amazon is pursuing new markets and disrupting industries at an incredible pace. Almost every industry seems to be in its crosshairs. Companies and industries that once thought they were safe are now worried about being “Amazoned.”. The new watch word should be “Be afraid. Be very afraid.” In his session 21st Cloud Expo, Chris Kocher, a co-founder of Grey Heron, will address questions such as: What new areas is Amazon disrupting? How are they doing this? Where are they likely to go? What are th...